Pictet Asset Management
IMVT icon

Pictet Asset Management’s Immunovant IMVT Stock Holding History

Pictet Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8M Sell
462,359
-10,022
-2% -$305K 0.02% 560
2026
Q1 		$11.7M Buy
472,381
+91,539
+24% +$2.37M 0.01% 615
2025
Q4 		$9.68M Sell
380,842
-295,735
-44% -$6.59M 0.01% 680
2025
Q3 		$10.9M Sell
676,577
-512,001
-43% -$8.29M 0.01% 654
2025
Q2 		$19M Hold
1,188,578
– – 0.02% 519
2025
Q1 		$20.3M Buy
1,188,578
+12,893
+1% +$270K 0.02% 494
2024
Q4 		$29.1M Sell
1,175,685
-54,624
-4% -$1.55M 0.03% 401
2024
Q3 		$35.1M Buy
1,230,309
+55,493
+5% +$1.64M 0.04% 359
2024
Q2 		$31M Sell
1,174,816
-90,482
-7% -$2.57M 0.04% 370
2024
Q1 		$40.9M Sell
1,265,298
-42,133
-3% -$1.54M 0.04% 348
2023
Q4 		$55.1M Buy
1,307,431
+172,226
+15% +$6.34M 0.06% 288
2023
Q3 		$43.6M Buy
+1,135,205
New +$25.7M 0.05% 308

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pictet Asset Management's IMVT Position: Q2 2026 in Review

Pictet Asset Management reduced its Immunovant (IMVT) stake by 2.1% in Q2 2026, selling an estimated $305K and leaving 462,359 shares worth $17.8M. The position accounts for 0.02% of the portfolio, ranked #560.

Pictet Asset Management first reported a position in IMVT in Q3 2023 and has held it in 12 quarters since. The position peaked at $55.1M in Q4 2023. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Pictet Asset Management held 462,359 shares of Immunovant worth $17.8M as of Q2 2026.
  • Pictet Asset Management sold 10,022 Immunovant shares in Q2 2026, an estimated $305K.
  • Immunovant made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #560 holding.
  • Pictet Asset Management first reported a position in Immunovant in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Immunovant position peaked at $55.1M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.